AccuKit-HIV utilizes AccuGenomics’ Standardized Nucleic Acid Quantification (SNAQ) technology and standardized molecular testing kit
WILMINGTON, NC, August 15, 2017 – AccuGenomics, Inc., a diagnostic company based in Wilmington, NC, today announced that the company has provided an AccuKit to the HIV Cure Center at the University of North Carolina at Chapel Hill and to Qura Therapeutics for evaluation in HIV research. AccuKit-HIV is designed to characterize and quantify HIV reservoir and viral expression in human CD4+ T cells before and after pharmacological intervention. The HIV Cure Center is a joint initiative between the University of North Carolina at Chapel Hill, NC (UNC) and GlaxoSmithKline (GSK), dedicated to developing a cure for HIV/AIDS. Qura Therapeutics is jointly owned by UNC-CH and GSK to manage the business side of the partnership.
“AccuGenomics is proud to provide our technology and evaluation methods to HIV Cure Center/Qura Therapeutics, for HIV/AIDS research and drug development,” said Tom Morrison, Ph.D., Chief Scientific Officer of AccuGenomics. “We support the mission of UNC HIV Cure Center and look forward to continuing our collaboration with them, one that supports their ultimate goal of finding a cure for HIV/AIDS.”
The AccuGenomics AccuKit is a standardized molecular testing kit, or screening assay. It is used to provide critical controls in test reactions, ensuring that test measurements achieve the required levels of sensitivity and linear response, independent of clinician, laboratory and time. The AccuKit in development by AccuGenomics utilizes the company’s Standardized Nucleic Acid Quantification (SNAQ) technology, used in clinical studies to enable accurate diagnosis and monitor responses to therapy. The AccuKit will be further qualified in vitro using clinical samples from fully-suppressed subjects by the HIV Cure Center/Qura Therapeutics, for accuracy, reproducibility and superiority compared to standard methods of measurement of the HIV reservoir in CD4+ T cells.
“We are pleased to be working with AccuGenomics,” said David Favre, DVM, PhD, Director, HIV Biology, GSK. “This joint collaboration is another example of bringing together the expertise and the capabilities from academic, biotech and industry institutions in order to address the scientific and technological challenges of developing a cure for HIV/AIDS.”
For more information about AccuGenomics, their diagnostic tools and their pipeline, please visit www.accugenomics.com.
AccuGenomics, Inc. is a diagnostic company headquartered in Wilmington, NC. Founded in 2010 by clinical researchers in the life sciences and diagnostic industries, AccuGenomics grew from a collaboration with the University of Toledo and the Innovative Molecular Analysis Technologies Program of the National Institutes of Health. Today, AccuGenomics is committed to improving patient outcomes by providing standardization technologies for multi gene expression tests that accurately diagnose, monitor and inform the treatment of diseases. Their leading technologies include Standardized Nucleic Acid Quantification (SNAQ), for use in quantitative polymerase chain reaction (PCR) platform analysis, and Standardized RNA Sequencing (STARSEQ), which ensures quality in next-generation sequencing (NGS). For more information or to discuss a partnership with AccuGenomics, please visit www.accugenomics.com or call 910.332.6522.
About Qura Therapeutics
The University of North Carolina at Chapel Hill and GlaxoSmithKline have partnered to focus on discovering a cure for HIV/AIDS through the formation of the UNC HIV Cure Center directed by Dr. David Margolis. UNC-CH and GSK have co-founded a jointly owned company, Qura Therapeutics, which handles the business side of the partnership. This incredibly unique public-private partnership is redefining the traditional way of conducting research and is creating a new model to seek the breakthroughs needed to tackle an extraordinarily challenging global health issue. “HIV Cure” means a therapeutic administration or a combination of administrations that alone or in combination with one or more other compounds induces and maintains sustained virologic remission and no disease progression after several years without any other therapeutic intervention. For more information, email Dr. Mary Napier at email@example.com.
Press Contact: Nick Lazaridis, Ph.D.